Centogene N.V. (CNTG)
| Previous Close | 4.6900 |
| Open | 4.5500 |
| Bid | 1.8900 x 900 |
| Ask | 8.1000 x 900 |
| Day's Range | 4.5002 - 4.7150 |
| 52 Week Range | 4.3300 - 14.0000 |
| Volume | |
| Avg. Volume | 29,869 |
| Market Cap | 101.751M |
| Beta (5Y Monthly) | -2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5920 |
| Earnings Date | Apr. 13, 2022 - Apr. 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.86 |
- GlobeNewswire
CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to utilize the power of proprietary reagent kits CENTOGENE is developing in collaboration with Twist Bioscience for rare disease diagnosticsCentoCloud provides rapid and reliable medical reports, which can be challenging for sequencing laboratories due to resource limitations as well as regulatory requiremen
- GlobeNewswire
CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery
Leveraging AI to Accelerate the Path From Diagnosis to CureCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it has been awarded the Health-i Award, which recognizes companies that are transforming healthcare in Germany and beyond. The Health-i Awards are sponsored by the Techniker Krankenkass
- GlobeNewswire
CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that its Chief Executive Officer, Andrin Oswald, M.D., is taking a temporary medical leave of absence for a period of at least four weeks. The accomplished biopharmaceutical industry executive Kim Stratton has been appointed as the Interim Chief Exe
